COMPARATIVE STUDY OF PHARMACOLOGICAL PROPERTIES AND PREDICTIONS FOR REPURPOSING OF GLIPTINS: A COMPUTATIONAL APPROACH

Dipeptidyl peptidase-IV (DPP-IV) inhibitors are widely used drugs of choice for treating Type 2 Diabetes Mellitus (T2DM).These are mostly gliptin molecules.DPP-IV is responsible for the degradation of Glucagon-like polypeptide -I which is responsible for the enhancement of the activity of the insulin.So, the therapeutic strategy is to use these drugs to inhibit DPP-enzyme, hence prohibiting the degradation of GLP-I.A series of DPP-IV inhibitors are used for the effective management of T2DM.Many DPP-IV inhibitors are still in clinical trials.The discovery and the need for developing novel DPP-IV inhibitors is the newer approach.These